Coherus BioSciences, Inc (CHRS) - Gross Profit Margin

Official company branding of Coherus BioSciences, Inc. (CHRS)

Coherus Biosciences (CHRS) is transforming its business by implementing proprietary immunotherapeutic developments in oncology. Growth is driven by sales of Loqtorzi, biosimilars, and cost reductions, with gross profit margin chart data sourced from GURU.Markets, where the value 63.30 corresponds to the current metric. This confirms its status as a biosimilar leader striving for profitability through debt optimization and operational efficiency.

CHRS (Coherus BioSciences, Inc) Return on Gross Profit history from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Coherus BioSciences (CHRS)

- market price and analyst price targets:
Basic company analysis:coherus.com (CHRS)
Manufactured products of coherus.com

Investors are assessing the resilience of Coherus Biosciences (CHRS) through its ability to generate profit after covering direct production costs. This metric determines the portion of revenue remaining after the cost of goods sold, allowing the relative gross margin to serve as a gauge of operational efficiency as the company strengthens its position in the immuno-oncology sector. The stability of this indicator confirms the market value of new treatment methods and the absence of any hidden erosion in the asset's profitability.